-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Bright Minds Biosciences, Lowers Price Target to $37

Benzinga·11/03/2026 08:44:52
Listen to the news
BTIG analyst Thomas Shrader maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and lowers the price target from $147 to $37.